| Popis: |
The China biotech industry is booming, amid government’s strong support owing to its recognition that biotech plays critical roles in human health, aging Chinese society and increasing the level of pollution, returning of Chinese students from overseas and home-grown talents, and ever-increasing funding and investment. The intellectual property protection is progressively strengthening. Recent regulatory reform at National Medical Products Administration has been sending fresh air and excitements to the China biotech industry to advance innovative drug clinical trials and registration. The US biotech and pharma companies need to take the advantage of these new progresses to accelerate the development and the entry of their innovative drugs to China, to compete with potential “me-too/better’s” and “fast follow-on’s” and capture the full value of their products in China. However, the pricing and reimbursement of innovative drugs are still uncertain at this time. New measures from the newly established State Medical Insurance Administration would clarify and improve the situation. Entrepreneurs and US biotech companies should take the advantage of the vast contract research organization resources and deep pockets of Chinese investors to advance their innovative technologies and drug candidates more rapidly and efficiently. However, Committee on Foreign Investment in the United States reviews under Foreign Investment Risk Review Modernization Act of 2018 and export control under Export Control Reform Act of 2018 might significantly hinder US biotech companies to receive investments from Chinese investors and to establish collaboration and licensing deals with Chinese companies. |
